Page 141 - CIBERER-2015-eng

Most relevant scientific articles
Research Groups
corVillo F, garcía-morato mB, noZal P, garrido s, tor- taJada a, de córdoBa sr, et al. Serum properdin con- sumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol. 2015 Dec 13. [Epub ahead of print] PubMed PMID: 26660535.
BernaBéu-herrero me, JiméneZ-alcáZar m, anter J, Pinto s, sáncheZ chinchilla d, garrido s, et al. Comple- ment factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol. 2015 Oct;67(2 Pt B):276-86.
ghannam a, sellier P, deFendi F, FaVier B, charignon d, lóPeZ-lera a, et al. C1 inhibitor function using con-
Highlights
The Group has a sustained research activity in the rare diseases atypical Haemolytic Uremic Syn- drome (aHUS), C3 glomerulopathy (C3G) and He- reditary Angioedema (HAE) while maintaining its translational actions by generating clinical data and diagnostic reports on patients affected of these pathologies. During 2015, the group has been fund by 3 MINECO projects headed by the group’s PIs: Margarita López Trascasa (SAF2012-386360), Pi- lar Sánchez-Corral Gómez (PI12/00597) and Tere- sa Caballero Molina (PI13/01758). Additionally, the group director has obtained funding for a new pro- ject entitled: Novel biomarkers in complement-me- diated diseases (PI15/00255). Regarding intramural actions, during 2015 the group has collaborated with CIBERER units U738 and U709 in a Common- Rare ACCI entitled “Pathogenic mechanisms in rare and common diseases associated to complement dysregulation” which has been renewed for 2016 (Complement and Disease. Search for pathogenic mechanisms shared by rare and common diseas- es). These actions allowed us for generating novel patient cohorts and developing novel tools for mo- lecular diagnosis which are now being evaluated.
tact-phase proteases as target: evaluation of an innova- tive assay. Allergy. 2015 Sep;70(9):1103-11.
martíneZ-Barricarte r, heurich m, lóPeZ-Perrote a, tortaJada a, Pinto s, lóPeZ-trascasa m, et al. The mo- lecular and structural bases for the association of com- plement C3 mutations with atypical hemolytic uremic syndrome. Mol Immunol. 2015 Aug;66(2):263-73.
BYgum a, aYgören-Pürsün e, Beusterien K, hautamaKi e, sisic Z, Wait s, et al. Burden of illness in hereditary an- gioedema: a conceptual model. Acta Derm Venereol. 2015 Jun 24;95(6):706-10.
Besides several International scientific publications, the main results of the group along 2015 have been presented in International conferences and the an- nual CIBERER meeting.
Moreover, in the present year, Pilar Sánchez Corral quit the European Complement Network’ scientific board after 4 years in the position, being replaced by Margarita López Trascasa.
As part of the group’s translational activities, we have participated in patients associations meetings on HAE (AEDAF) and aHUS (ASHUa).
Among the formative activities during the evaluated period, it is worth noting the PhD thesis presented by Nieves Prior Gómez: Development and validation of HAE-QoL (a specific health-related quality-of-life questionnaire for adult patients with Hereditary Angioedema due to C1-Inhibitor deficiency) (direct- ed by Dr. Teresa Caballero Molina) at Universidad Autónoma de Madrid with cum laude distinction.
Institution: Servicio Madrileño de Salud · Contact: Hospital La Paz
Paseo de la Castellana, 261 28046 Madrid · Tel.: 91 207 14 63 · E.mail: [email protected]
CIBERER I Annual report 2015 I 141